{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.312","value":"-2.78"},{"groupId":"OG001","spread":"14.912","value":"7.02"},{"groupId":"OG002","spread":"41.335","value":"1.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.172","value":"0.00"},{"groupId":"OG001","spread":"11.011","value":"-1.39"},{"groupId":"OG002","spread":"41.574","value":"-22.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 9, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.878","value":"-1.59"},{"groupId":"OG001","spread":"12.669","value":"-6.67"},{"groupId":"OG002","spread":"18.257","value":"-5.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 13, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.355","value":"9.26"},{"groupId":"OG001","spread":"10.924","value":"1.85"},{"groupId":"OG002","spread":"16.355","value":"-12.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.830","value":"0.00"},{"groupId":"OG001","spread":"11.111","value":"11.11"},{"groupId":"OG002","spread":"14.344","value":"-16.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"Cycle 21, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.713","value":"0.00"},{"groupId":"OG001","spread":"7.857","value":"27.78"},{"groupId":"OG002","spread":"7.857","value":"-5.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Cycle 25, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.962","value":"3.70"},{"groupId":"OG001","spread":"15.713","value":"22.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 29, Day 1"},{"categories":[{"measurements":[{"comment":"Not estimable due to sample size","groupId":"OG000","spread":"NA","value":"11.11"},{"comment":"Not estimable due to sample size","groupId":"OG001","spread":"NA","value":"33.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 33, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.903","value":"-1.59"},{"groupId":"OG001","spread":"30.820","value":"7.87"},{"groupId":"OG002","spread":"31.427","value":"-44.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Safety Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"Mean change from baseline at safety follow-up visit in EORTC QLQ-C30 Fatigue score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes questions related to fatigue symptoms in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a higher score indicating improved health status.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG000","title":"Cohort 1: ENKTL"},{"description":"Participants with other R/R mature T-cell neoplasms \\[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG001","title":"Cohort 2: PTCL-NOS, AITL, and ALCL"},{"description":"Participants with R/R cutaneous T-cell lymphoma \\[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG002","title":"Cohort 3: MF and SS"}],"paramType":"MEAN","populationDescription":"Safety analysis set includes all participants who received at least one dose of study drug. The number analyzed represents participants who completed the questionnaire.","reportingStatus":"POSTED","timeFrame":"Baseline and on Day 1 in Cycles 5, 9, 13, 17, 21, 25, 29, and 33 (21 days per cycle) and safety follow-up visit (up to 30 days after end of treatment; up to approximately 3 years and 1 week)","title":"Quality of Life Assessment: EORTC QLQ-C30 Change From Baseline in Fatigue Score","type":"SECONDARY","unitOfMeasure":"Score on a scale"}